Table 4. Hazard ratios for mortality and recurrence associated with lipid-lowering drug use at recruitment, compared to past or never use.

		crude*		adjusted**
Patients	Outcome	n	HR (95% CI)	n	HR (95% CI)
stage I–IV	Overall mortality	3189	1.25 (0.93–1.70)	3085	1.21 (0.87–1.69)
	Breast cancer-specific mortality	3189	1.08 (0.73–1.59)	3085	1.04 (0.67–1.60)
	Non-breast cancer mortality	3189	1.66 (1.02–2.69)	3085	1.49 (0.88–2.52)
stage I–III	Overall mortality	3024	1.18 (0.85–1.66)	2936	1.12 (0.77–1.62)
	Breast cancer-specific mortality	3024	0.96 (0.60–1.53)	2936	0.89 (0.52–1.49)
	Non-breast cancer mortality	3024	1.58 (0.96–2.59)	2936	1.43 (0.84–2.44)
	Recurrence	2996	0.91 (0.63–1.32)	2912	0.83 (0.54–1.24)
stage I–III, only postmenopausal	Overall mortality	2755	1.15 (0.81–1.62)	2671	1.14 (0.78–1.66)
	Breast cancer-specific mortality	2755	0.89 (0.55–1.45)	2671	0.93 (0.54–1.60)
	Non-breast cancer mortality	2755	1.60 (0.97–2.63)	2671	1.44 (0.84–2.46)
	Recurrence	2729	0.88 (0.60–1.28)	2649	0.84 (0.57–1.26)

^*stratified by region, adjusted for age.

^**stratified by region, tumor grade, estrogen/progesterone receptor status; adjusted for age, the traditional prognostic factors tumor size, nodal status, (metastases, stage I–IV only), and for the following additional covariates evaluated using backward elimination: menopausal hormone treatment at recruitment, mode of detection, radiotherapy, and smoking. Mortality analyses are additionally adjusted for cardiovascular disease, diabetes mellitus, and body-mass index.